Description

Aflibercept CAS NO 862111-32-8 is a recombinant fusion protein designed as a potent vascular endothelial growth factor (VEGF) inhibitor. This compound is of critical importance in advanced therapeutic applications, primarily for its ability to block angiogenesis by binding to VEGF-A, VEGF-B, and placental growth factor (PlGF). It is an essential active pharmaceutical ingredient (API) for pharmaceutical manufacturers and research institutions developing treatments for neovascular (wet) age-related macular degeneration (AMD), macular edema, and certain metastatic cancers. Its targeted mechanism offers a high-value solution for creating next-generation biopharmaceuticals.

Application

• Primary API in the manufacture of ophthalmic injectable solutions for neovascular age-related macular degeneration (wet AMD).
• Key therapeutic agent in formulations for the treatment of macular edema following retinal vein occlusion (RVO).
• Critical component in oncology drugs targeting metastatic colorectal cancer and other VEGF-driven tumors.
• Active ingredient for diabetic macular edema (DME) treatment regimens.
• Reference standard in bioanalytical research and pharmacokinetic studies.
• Essential material for biosimilar development and comparability testing.
• Used in pre-clinical and clinical trial material (CTM) production.
• Vital reagent in academic and institutional research on angiogenesis and vascular biology.

Basic Information

Product Name	Aflibercept
CAS No.	862111-32-8
Molecular Formula	C4318H6788N1164O1304S32
Molecular Weight	96.9 kDa (Approx.)
Synonyms	VEGF Trap; Aflibercept (USAN); Eylea (Brand Name); Zaltrap (Brand Name); Recombinant Fusion Protein VEGF Trap; Vascular Endothelial Growth Factor Trap; VEGF Receptor Fusion Protein; BAY 86-5321; Contact for details on additional aliases.
EINECS	Not applicable for biopharmaceuticals.

Quality Control

Our Aflibercept is manufactured under strict quality systems. Each batch is subjected to a comprehensive battery of analytical tests to ensure identity, purity, potency, and safety, aligning with ICH guidelines. We provide full traceability and support regulatory filings with detailed documentation. Certificates of Analysis (COA) are available upon request, detailing specifications for purity, biological activity, endotoxin levels, and process-related impurities.

Storage

Preserve in a tightly closed container, protected from light. Store frozen at -20°C to -80°C for long-term stability. For short-term or in-use storage, maintain at 2-8°C. This product is hygroscopic (moisture-sensitive); ensure containers are sealed under controlled humidity conditions to prevent degradation. Avoid repeated freeze-thaw cycles.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear solution
Identification (HPLC/MS)	Conforms to reference standard
Purity (SDS-PAGE & SEC-HPLC)	≥ 98.0%
Protein Content (UV Absorbance)	As per COA
Biological Activity (Cell-based Assay)	≥ 95% relative potency
Endotoxin (LAL)	< 1.0 EU/mg
Host Cell Proteins (HCP ELISA)	< 100 ppm
Residual DNA (qPCR)	< 10 pg/mg
pH	6.0 - 7.5 (in solution)
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.